Unlocking HIV Care: Are Single Tablet Regimens the Key to Better Health?
"Explore the impact of simplifying HIV treatment on managing other health conditions. Is one pill really better?"
For individuals living with HIV, advancements in antiretroviral therapy (ART) have dramatically improved health outcomes and extended lifespans. As a result, many HIV-positive individuals now face the challenge of managing additional health conditions, or comorbidities, that are often associated with aging. These can include conditions like hypertension, diabetes, and dyslipidemia, creating a complex web of healthcare needs.
Managing both HIV and these additional health issues often requires taking multiple medications—a situation known as polypharmacy. Polypharmacy can lead to reduced adherence to medication schedules, increasing the risk of treatment failure and other complications. This is where single-tablet regimens (STRs) come into play. STRs combine multiple medications into a single pill, aiming to simplify treatment and improve adherence.
But does simplifying HIV treatment with STRs actually lead to better control of these other health conditions? This is the question that researchers have been exploring, seeking to understand whether the convenience of a single pill can translate into tangible health benefits beyond just managing the HIV virus itself.
The Cornerstone of Modern HIV Treatment
Single-tablet regimens (STRs) have become ubiquitous in HIV treatment and are now considered the cornerstone of antiretroviral therapy. Studies presented at major conferences support the use of novel STRs over more complex, multi-tablet treatment options. However, the potential reintroduction of generic multi-tablet regimens as a cost-reducing strategy highlights the need to balance clinical effectiveness with economic considerations.
Improving Adherence, But Not Without Limitations
Single-tablet regimens have been shown to improve antiretroviral adherence and reduce hospitalization compared to multiple-tablet regimens. A longitudinal study found that patients switching from a multi-tablet to a single-tablet regimen experienced better treatment retention and viral suppression. However, all currently marketed single-tablet coformulations are produced by Gilead Sciences, and there are no protease inhibitor-based single-tablet regimens available.
The Evolution to Single-Tablet Regimens
Single-tablet regimens represent the culmination of the evolution in antiretroviral therapy for HIV-1 infection. Currently, there are five single-tablet regimens available, with three being recommended for treatment-naïve patients. The development of the single-tablet regimen containing darunavir/cobicistat/emtricitabine/tenofovir alafenamide marks a significant milestone in providing effective, simplified treatment.
The STR vs. MTR Debate: What the Research Says
A recent study investigated whether using STRs could help HIV-infected patients better manage their comorbidities compared to those taking multiple-tablet regimens (MTRs). The study, published in the Journal of HIV & Retro Virus, looked at a group of adult HIV-infected veterans receiving care within the Upstate New York Veterans' Affairs Healthcare Network. Researchers compared how well patients on STRs and MTRs were able to control conditions like blood pressure, glucose levels, and lipid levels.
- The study included 1,202 subjects, with 165 receiving STRs and 1,037 on MTRs.
- The average age of participants was about 50.6 years.
- Most participants were male (97.2%), with a mix of Caucasian (45.8%) and Black (49.8%) individuals.
- Researchers found no significant differences in achieving or maintaining control of cardiometabolic comorbidities between the STR and MTR groups.
Innovations in Single-Tablet Regimens
Recent research highlights the development of novel single-tablet regimens that demonstrate noninferiority to standard HIV therapy. Data presented at CROI 2026 showed that two new oral daily single-tablet therapies, including bictegravir/lenacapavir, not only simplify treatment but also provide metabolic benefits such as reduced lipids. Furthermore, Gilead has submitted a New Drug Application to the FDA for a single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide, expanding treatment options.
Virologic Superiority But Remaining Challenges
A study found that patients taking a single-tablet regimen had a significantly greater CD4 increase compared to those on multiple-tablet regimens. At 12 months, 82% of patients on a single-tablet regimen achieved an undetectable viral load, versus 66% on a multiple-tablet regimen. However, this superior virologic response does not fully address other challenges such as cost, drug interactions, or individual patient adherence patterns.
Evidence from Meta-Analyses and Real-World Studies
A meta-analysis comparing 48-week treatment outcomes found that single-tablet regimens are associated with better adherence and viral suppression than multiple-tablet regimens. Real-world studies among US Medicaid beneficiaries show that single-tablet regimens improve treatment persistence and virologic outcomes. However, there remain limited outcomes data directly comparing single-tablet to multiple-tablet regimens in diverse populations.
The Future of HIV Treatment: A Holistic Approach
While this study suggests that STRs may not directly improve comorbidity control, they remain a valuable option for simplifying HIV treatment and potentially improving adherence. The researchers emphasize that future studies should continue to explore the impact of different ART regimens on both HIV and non-HIV health outcomes. As newer STR products become available, it will be important to reassess their effects in diverse patient populations. Ultimately, the best approach to HIV care involves a holistic strategy that considers individual patient needs, preferences, and overall health goals.
Expert Perspectives on Single-Tablet Regimens
Expert opinion acknowledges that while single-tablet regimens offer benefits in adherence and quality of life, they also have clinical limitations related to adverse event profiles, drug interactions, and variable barriers to resistance. Pharmacoeconomic evaluations suggest that the higher costs of single-tablet regimens may be offset by improved outcomes. The case of the single-tablet regimen consisting of bictegravir/emtricitabine/tenofovir alafenamide illustrates how a single pill can contain all necessary ingredients for successful treatment.
Addressing Pill Fatigue with Once-Weekly Regimens
Once-weekly HIV pills are showing promise in phase 3 trials, offering a potential solution to daily pill fatigue and adherence challenges. Research indicates that once-daily single-tablet regimens have transformed the outlook for millions, but daily pill fatigue remains a barrier for some patients. The development of once-weekly regimens could further improve adherence and quality of life for people living with HIV.
A New Era, But Systemic Challenges Persist
Single-tablet regimens represent a new era of antiretroviral therapy, with studies showing better treatment retention and viral suppression compared to multiple-tablet regimens. However, systemic challenges such as cost, access, and equity remain significant barriers to optimal HIV care globally. The benefits of simplified treatment must be balanced against these broader healthcare system issues.
Real-World Durability and Cost Considerations
Real-world evidence shows that single-tablet regimens are durable and generally well tolerated when patients switch from multi-tablet regimens, with no new significant safety concerns. However, single-tablet formulations can be more costly than multi-tablet regimens, though higher costs may be offset by enhanced efficacy resulting from improved adherence. Studies in cohort settings demonstrate the long-term effectiveness of single-tablet regimens in treatment-naïve patients.